Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Ireland / NCT05986253
Active, not recruiting Not applicable

BioDulse II: The Effect of an Irish Seaweed Protein Extract on Glucose Control in Adults With Type 2 Diabetes

NCT05986253 · tracked via the Priya Life Science Ireland tracker
Sponsor
University of Limerick
Phase
Not applicable
Started
2023-08-07
Last updated
2024-04-09

Condition(s) studied

Type 2 Diabetes

Investigational drug(s) / intervention(s)

Seaweed proteinMaltodextrin

Seaweed protein: Novel protein extracted from seaweed

Maltodextrin: maltodextrin solution

Study summary

Co-ingesting protein with carbohydrate is an effective way to improve postprandial glucose handling. The investigators have isolated and identified a bioactive protein extracted from seaweed. The investigators aim to explore how varying doses of seaweed protein influence postprandial glycaemia and insulinaemia in a population with type 2 diabetes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
67 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 18-67 Exclusion Criteria: * Terminal disease * Exclusively receiving enteral or parenteral nutrition * Any conditions/anomalies that are contraindications to bioelectrical impedance analysis as per institutional risk assessment and standard operating procedures * Past medical history of cancer, neurological, kidney, pulmonary, digestive (Coeliac disease), thyroidal disease, cognitive impairment

Primary outcome measure(s)

  • Postprandial blood glucose area under the curve (AUC) — 120 minutes
    Integrated area under curve of blood glucose concentration (measured as mmol/L) over 120 minutes

Trial sites (1)

FacilityCityRegionStatus
University of Limerick Limerick Ireland

More University of Limerick trials in Ireland

Profiling Patients With Rotator Cuff Related Shoulder Pain: What Factors Influence Outcomes With Non-operative Care in a Secondary Care Specialist Shoulder Clinic? Recruiting
Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study Recruiting
The Impact of Domiciliary Versus 'Hub' Based Comprehensive Geriatric Assessment on Clinical and Process Outcomes Among Older Adults Attending Community Specialist Teams: a Randomised Controlled Trial. Active, not recruiting
Community-based Exercise for Older Adults With Chronic Musculoskeletal Pain Recruiting
Inpatient Post-Acute Rehabilitation For Patients in the Midwest: a Prospective Cohort Study of Clinical Characteristics and Process Outcomes Recruiting

Other trials for the same condition

Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05986253 on ClinicalTrials.gov ↗ ← All trials in Ireland